Management of lentigo maligna and lentigo maligna melanoma: Seminars in surgical oncology

Hand tumors of the skin and soft tissue are frequently encountered by plastic surgeons. Although similar to lesions affecting other parts of the body, the presentation, workup, and treatment options often differ in the hand secondary to its complex anatomy and functional significance. The purpose of this article is to provide an overview of those lesions that commonly arise in the hand-including epidermal inclusion cysts, ganglion cysts, and glomus tumors-in addition to tumors such as soft-tissue sarcomas that are rare but nonetheless require astute diagnosis and expedient initiation of treatment. Presenting symptoms and clinical features, recommended workup, and appropriate treatment options are reviewed.

show abstract

“…40 Surgical excision remains the recommended treatment. Accepted surgical margins for cutaneous melanoma Table 1.…”

Section: Melanomamentioning

confidence: 99%

Hand Tumors

Henderson¹,

Neumeister²,

Bueno³

2014

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Topical Tretinoin, Lung Cancer, and Lung-Related Mortality A mid continuing controversies over drug safety, 1,2 results of a trial of topical tretinoin-a commonly used medication for acne 3 and skin wrinkles, hyperpigmentation, and roughness 4 -raise serious concerns for the public health. The Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial 5,6 was a vehicle-controlled randomized controlled trial (RCT) that studied whether topical tretinoin, 0.1%, cream applied to the face and ears could prevent nonmelanoma skin cancer.…”

Section: Comments and Opinionsmentioning

confidence: 99%

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

L entigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma. 1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm. 2 A margincontrolled excision using "slow Mohs" (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%. 3Methods. Thirty-two patients with 34 histologically confirmed facial LM lesions were enrolled in an open-label trial of imiquimod, 5%, cream (Aldara; 3M Pharma, Rueschlikon, Switzerland). No patient had been treated

show abstract

“…Among dermatologists, there is substantial variability in the management of melanoma in situ (MIS). Despite several recently published reviews of treatment options for MIS, 1–4 current data suggest that there is little consensus among dermatologists regarding the appropriate surgical margins or depth of excision for MIS 5 . In addition, many dermatologists are uncertain about the rate of progression of MIS lesions to metastatic disease if left untreated 5 …”

mentioning

confidence: 99%